Efficas for Asthma Product Info

Asthma is a common chronic, inflammatory disease of the airways characterized by variable and recurring symptoms affecting both children and adults. These symptoms include wheezing, coughing, chest tightness, and shortness of breath. Asthma symptoms can result in sleep disruption and limitations on exercise, work or school activities. Long-term effects may include a progressive decline in lung function or, in children, reduced lung growth and reduced height. Severe asthma attacks may require hospitalization and can cause death.

EFFICAS for Asthma is a patented technology based on a unique combination of safe and naturally occurring essential fatty acids which are delivered in a highly bioavailable, good tasting liquid form which is highly effective for pediatrics through adults. The combination of these natural fatty acids safely reduces the production of leukotrienes by a nutritional mechanism of action. The overproduction leukotrienes are responsible for inflammation and asthma symptoms.

To learn more about Efficas for Asthma, visit us at or email us at #efficas

Efficas Product Video

To learn more about Efficas for Asthma, visit us at or email us at #efficas


Efficas for Asthma Product Highlights

Here are some Efficas for Asthma’s Product Highlights

  • Consumer tested, 28 days Home Use Test, with consumers experiencing a dramatic improvement and product performance greater than many pharmaceutical products used for allergic conditions including asthma.
  • Patented technology
  • All natural product, non-steroidal
  • Once-a-day oral liquid formulation
  • Medical food platform for specific dietary management of allergic diseases
  • Excellent safety profile in ages 2 years and older
  • Expert Panel-Affirmed GRAS status in the US
  • Clinically tested to reduce leukotriene production
  • Clinically tested demonstrating improved quality of life in asthmatics

To learn more about Efficas for Asthma, visit us at or email us at #efficas

Practitioner Information – Consumer Study

Practioner Information: Open-label consumer study in adults with asthma

  • Nation-wide study during summer allergy season
  • 101 subjects enrolled and responded to Day 1 questionnaires
  • Consumed the medical food for 28 days
  • 70% reported an improvement in their condition (N= 95)
  • 74% had clinically meaningful* improvement in MiniAQLQ** total score (N = 65)
  • Statistically significant change in MiniAQLQ total score by paired t-test (N = 65) p<0.001
  • Significant decrease in inhaler use scores from ACQ (N = 65) p<0.001

*   Score increase > 0.5 units